HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Karp, R. B. Articles by Pacifico, A. D. Search for Related Content PubMed PubMed Citation Articles by Karp, R. B. Articles by Pacifico, A. D.

The Journal of Thoracic and Cardiovascular Surgery, Vol 81, 602-614, Copyright © 1981 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

The Bjork-Shiley valve: intermediate-term follow-up

RB Karp, RJ Cyrus, EH Blackstone, JW Kirklin, NT Kouchoukos and AD Pacifico

We evaluated 643 patients surviving aortic, mitral, and aortic and mitral ("double") valve replacement with the Bjork-Shiley prosthesis from 1 to 72 months (median 38 months) postoperatively. Intermediate- term survival rate was similar to that reported for other prosthetic and bioprosthetic devices. Factors unrelated to the device, but related to preoperative patient characteristics or intraoperative or early postoperative events, had important association with late survival rate. These included previous valve replacement, concomitant ventricular aneurysm resection, black race, preoperative functional class, method of myocardial protection, duration of ischemic arrest, ventricular arrhythmias, and double valve replacement. Concomitant coronary artery bypass grafting and the type of valve lesion had no effect on survival prognosis. Freedom from thromboembolism was equal to or superior to other devices, but valve thrombosis occurred 16 times in 15 patients and caused 13 deaths. Improvement in New York Heart Association (NYHA) functional class occurred in the majority of patients. We conclude that the Bjork-Shiley valve is durable and effective, but, as with other devices, is associated with problems of thromboembolism and thrombosis. Intermediate-term survival is related also to non-device, patient-associated characteristics.

This article has been cited by other articles:

				S. B Kale, D. S Saksena, Y. C Agnihotri, and K. H Ayyer Thrombectomy With Disc Rotation of Medtronic Valves Asian Cardiovasc Thorac Ann, December 1, 2003; 11(4): 309 - 313. [Abstract] [Full Text] [PDF]

				S. Dhawan, P. Sharma, and T. Tak Thrombotic Occlusion of Bjork-Shiley Prosthetic Aortic Valve Clin. Med. Res., October 1, 2003; 1(4): 305 - 308. [Abstract] [Full Text] [PDF]

				S. John, E. Ravikumar, C. N. John, and V. V. Bashi 25-year experience with 456 combined mitral and aortic valve replacement for rheumatic heart disease Ann. Thorac. Surg., April 1, 2000; 69(4): 1167 - 1172. [Abstract] [Full Text] [PDF]

				N. Sharma, A. Grover, and B. D. Radotra Prosthetic Cardiac Valve Replacement: Management Problems Asian Cardiovasc Thorac Ann, September 1, 1998; 6(3): 179 - 182. [Abstract] [Full Text] [PDF]

				J.F. Lopez, B. Bharadwaj, and S. Lal Experience with Hall-Kaster Valves Vascular and Endovascular Surgery, January 1, 1990; 24(1): 16 - 22. [Abstract] [PDF]